Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Issa F. Khouri,Peter McLaughlin,Rima M. Saliba,Chitra Hosing,Martin Korbling,Ming S. Lee,L. Jeffrey Medeiros,Luis Fayad,Felipe Samaniego,Amin M. Alousi,Paolo Anderlini,Daniel R. Couriel,Marcos de Lima,Sergio Giralt,Sattva S. Neelapu,Naoto T. Ueno,Barry I. Samuels,Fredrick B. Hagemeister,Larry W. Kwak,Richard E. Champlin +19 more
TLDR
The described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma and all 18 patients who were tested and had evidence of JH/bcl-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission.About:
This article is published in Blood.The article was published on 2008-06-15 and is currently open access. It has received 291 citations till now. The article focuses on the topics: Recurrent Follicular Lymphoma & Follicular lymphoma.read more
Citations
More filters
Journal ArticleDOI
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G. Till,Brian G. Till,Michael C. Jensen,Jinjuan Wang,Eric Y. Chen,Brent L. Wood,Harvey A. Greisman,Xiaojun Qian,Scott E. James,Andrew Raubitschek,Stephen J. Forman,Ajay K. Gopal,Ajay K. Gopal,John M. Pagel,John M. Pagel,Catherine G. Lindgren,Philip D. Greenberg,Philip D. Greenberg,Stanley R. Riddell,Stanley R. Riddell,Oliver W. Press,Oliver W. Press +21 more
TL;DR: The results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T- cell receptor and neomycin resistance gene show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach.
Journal ArticleDOI
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: This work presents a meta-analysis of 120 cases of central giant cell granuloma in mice over a 12-month period and shows clear trends in survival and morbidity during the first year of treatment with chemotherapy.
Journal ArticleDOI
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Brian G. Till,Brian G. Till,Michael C. Jensen,Michael C. Jensen,Jinjuan Wang,Xiaojun Qian,Ajay K. Gopal,Ajay K. Gopal,David G. Maloney,David G. Maloney,Catherine G. Lindgren,Yukang Lin,John M. Pagel,John M. Pagel,Lihua E. Budde,Lihua E. Budde,Andrew Raubitschek,Stephen J. Forman,Philip D. Greenberg,Philip D. Greenberg,Stanley R. Riddell,Stanley R. Riddell,Oliver W. Press,Oliver W. Press +23 more
TL;DR: A pilot clinical trial testing a "third-generation" CD20-specific CAR with CD28 and 4-1BB costimulatory domains in patients with relapsed indolent B-cell and mantle cell lymphomas found that adoptive immunotherapy with CD 20-specific T cells was well tolerated and was associated with antitumor activity.
Journal ArticleDOI
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.
TL;DR: The definition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens are provided.
Journal ArticleDOI
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.
Per Ljungman,Marco Bregni,Mats Brune,Jan J. Cornelissen,T. de Witte,Giorgio Dini,Herman Einsele,H. B. Gaspar,Alois Gratwohl,Jakob Passweg,C Peters,Vanderson Rocha,Riccardo Saccardi,Harry C. Schouten,Anna Sureda,André Tichelli,Andrea Velardi,Dietger Niederwieser +17 more
TL;DR: An updated report with revised tables and operating definitions is presented on the current practice of haematopoietic SCT for haem atological diseases, solid tumours and immune disorders in Europe.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
The Statistical Analysis of Failure Time Data.
Journal ArticleDOI
The Statistical Analysis of Failure Time Data
TL;DR: This book complements the other references well, and merits a place on the bookshelf of anyone concerned with the analysis of lifetime data from any eld.
Journal Article
1994 Consensus Conference on Acute GVHD Grading.
Donna Przepiorka,Daniel J. Weisdorf,Paul J. Martin,Hans G. Klingemann,Beatty P,Hows J,Thomas Ed +6 more
TL;DR: Reports of GVHD prevention trials should include an accurate description of the grading system used and should report actuarial rates of grades II-IV and III-IV GV HD corrected for graft failure and potential interventions for early relapse.
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Related Papers (5)
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
Koen van Besien,Fausto R. Loberiza,Ruta Bajorunaite,James O. Armitage,Asad Bashey,Linda J. Burns,Cesar O. Freytes,John Gibson,Mary M. Horowitz,David J. Inwards,David I. Marks,Rodrigo Martino,Richard T. Maziarz,Arturo Molina,Santiago Pavlovsky,Andrew L. Pecora,Harry C. Schouten,Thomas C. Shea,Hillard M. Lazarus,J. Douglas Rizzo,Julie M. Vose +20 more
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more